This article provides an overview of potential tools being explored in Germany by Health Insurance Funds to better control drug prices and healthcare spend, offering insight into which measure may be implemented.
David Bower
Advertisement
Principal at Clarion, and Head of Market Access & Pricing
Articles by David Bower
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
MJH Life Sciences Acquires BPD Healthcare, Expands Reach Among Health Systems and Innovators
3
Bob Mauch: Strengthening the Chain
4
Takeda and Innovent Biologics Announce Strategic Global Partnership
5
